Company News

Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+™, with BioHorizons Implant…

Orthocell has today published its Quarterly Report for the period ended 31 March 2022. Standout achievements for this Quarter include:…

Orthocell’s Remplir™ device has gained Australian regulatory (Therapeutics Goods Administration) approval.

Orthocell’s Striate+™ dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum.

On International Day of Women In Science, we’re proud to shine a spotlight on Orthocell’s Quality Director, Monique Cannon.

Orthocell (ASX $OCC) has today published its Quarterly Report for the period ended 31 December 2021.

Orthocell (ASX $OCC) has today released positive clinical data for its OrthoATI™ tendon program, which shows that OrthoATI™ is statistically more…

Orthocell (ASX $OCC) has today released an update on its Ortho-ATI™ rotator cuff tendon study – the database is now…

Orthocell’s CelGro™ technology has been featured as one of only four case studies in the recent Australian Regenerative Medicine Therapies…

Orthocell MD, Paul Anderson, presented at the Canaccord Genuity South-West Connect ASX Showcase today to share the latest news and…